To conclude, the lack of efficacy of PD‐217,014 in our study suggests that if earlier α2δ ligands do indeed have efficacy in reducing abdominal pain in IBS, then this efficacy does not extend to all members of this pharmacological class, whether suffering with high levels of pain and/or anxiety, or not. The gene discussed is ATXN2L; the disease is irritable bowel syndrome.